Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Current Leases (2020 - 2025)

Gain Therapeutics has reported Current Leases over the past 6 years, most recently at $115910.0 for Q3 2025.

  • Quarterly results put Current Leases at $115910.0 for Q3 2025, down 35.17% from a year ago — trailing twelve months through Sep 2025 was $115910.0 (down 35.17% YoY), and the annual figure for FY2024 was $160913.0, down 29.94%.
  • Current Leases for Q3 2025 was $115910.0 at Gain Therapeutics, down from $136320.0 in the prior quarter.
  • Over the last five years, Current Leases for GANX hit a ceiling of $235798.0 in Q2 2023 and a floor of $115910.0 in Q3 2025.
  • Median Current Leases over the past 5 years was $204569.0 (2024), compared with a mean of $191368.7.
  • Biggest five-year swings in Current Leases: surged 83.22% in 2022 and later plummeted 35.17% in 2025.
  • Gain Therapeutics' Current Leases stood at $219137.0 in 2021, then grew by 4.54% to $229080.0 in 2022, then rose by 0.27% to $229693.0 in 2023, then fell by 29.94% to $160913.0 in 2024, then fell by 27.97% to $115910.0 in 2025.
  • The last three reported values for Current Leases were $115910.0 (Q3 2025), $136320.0 (Q2 2025), and $148674.0 (Q1 2025) per Business Quant data.